Anagenics Limited · ASX:AN1

Anagenics — Cellmid — Investor Presentation (July 2018)

30 slides from Anagenics's investor presentation, July 2018

  1. Slide 1: Investor Presentation July 2018

    Slide 1: Investor Presentation July 2018

    For personal use only INVESTOR PRESENTATION CEO Maria Halasz JULY 2018 ASX: CDY

  2. Slide 2: Focused on scaling multi-channel distribution of clinically proven products

    Slide 2: Focused on scaling multi-channel distribution of clinically proven products

    For personal use only Focused on rapidly scaling the multi- channel distribution of flagship, clinically proven product ranges in Asia, USA and Australia. Continue to extract value from midkine drug development and patent portfolio “I feel younger, you know, like in my 30’s” 2

  3. Slide 3: Company Overview

    Slide 3: Company Overview

    COMPANY OVERVIEW Cellmid has three wholly owned subsidiaries operating in two distinct business segments. For personal use only CONSUMER HEALTH PRE-CLINICAL THERAPEUTIC ASSETS ADVANGEN Anti-aging functional cosmetics and consumer health products for hair, face and wellbeing. Product range includes a

  4. Slide 4: Investment Highlights

    Slide 4: Investment Highlights

    INVESTMENT HIGHLIGHTS For personal use only Highly experienced Existing distribution Proprietary, Exposure to the fast Near term growth Midkine drug board and networks in clinically validated growth anti-aging via new product portfolio management team Australia, Japan, products that segment of the r

  5. Slide 5: A Strong Board

    Slide 5: A Strong Board

    A STRONG BOARD A vibrant mix of global retail, life sciences and finance experience For personal use only Dr David King | Chairman Maria Halasz | CEO and Managing Director GOVERNANCE ENTREPRENEURSHIP LIFE SCIENCES RETAIL FINANCE ENTREPRENEURSHIP An experienced independent chairman with expertise in

  6. Slide 6: Advangen

    Slide 6: Advangen

    For personal use only ADVANGEN Positive Aging 6

  7. Slide 7: What is evolis?

    Slide 7: What is evolis?

    WHAT IS ? is a clinically validated, TGA listed portfolio of haircare For personal use only treatment products specifically formulated as an anti-aging hair solution, combining science and nature to bring back your best hair. is the culmination of over 10 years of dedicated research into hair growth

  8. Slide 8: Addressing a Global Hair Growth Problem

    Slide 8: Addressing a Global Hair Growth Problem

    ADDRESSING A GLOBAL HAIR GROWTH PROBLEM USA For personal use only 18 million men and women are suffering from hair loss in the US PRODUCT RANGE • 13% of women experience hair loss by 40 increasing up to 50% by age 70 and • 50% of men experience significant hair loss by age 50 PROFESSIONAL Reverse, P

  9. Slide 9: How Does evolis Work?

    Slide 9: How Does evolis Work?

    HOW DOES WORK ? • FGF5 is a naturally occurring protein and critical in the hair cycle For personal use only • Its role is to signal hair to stop growing • Blocking FGF5 can extend the growth phase of hair resulting in increased hair growth, reduced hair loss and longer, stronger and thicker hair •

  10. Slide 10: Market Opportunity

    Slide 10: Market Opportunity

    MARKET OPPORTUNITY ANTI-AGING For personal use only GLOBAL HAIRCARE HAIRLOSS forecast to grow MARKET 24% Forecasted to reach 2018-2022 with emerging US$11.8B markets expected to generate double digit growth3 by 2024 1 GLOBAL HAIRCARE MARKET outperformed fast is estimated to be growing anti-aging hai

  11. Slide 11: Competitive Landscape

    Slide 11: Competitive Landscape

    COMPETITIVE LANDSCAPE évolis® is the only anti-aging haircare product that is based évolis® ticks all the boxes For personal use only on natural ingredients, clinically and scientifically validated and effective in reducing hair loss and increasing hair growth évolis® vs. other anti-aging brands2. é

  12. Slide 12: What is Fillerina?

    Slide 12: What is Fillerina?

    WHAT IS FILLERINA® ? Fillerina® is the first non-injectable transdermal filler For personal use only that has been clinically validated to reduce wrinkles and increase facial volume. The Fillerina® treatment combines six hyaluronic acids to facilitate the filling in and plumping up of tissues. In De

  13. Slide 13: The Distribution Agreement

    Slide 13: The Distribution Agreement

    THE DISTRIBUTION AGREEMENT For personal use only • Advangen has entered into an agreement with Labo WHY FILLERINA® ? International to undertake the exclusive distribution of Fillerina® in AU & NZ (launch September 2018) • First in class, best in class non-injectable • Second product within Advangen

  14. Slide 14: Strong Revenue Growth in Advangen to Date

    Slide 14: Strong Revenue Growth in Advangen to Date

    STRONG REVENUE GROWTH IN ADVANGEN TO DATE, FY2019 EXPECTED TO BE A BREAKOUT YEAR Q1-Q3 FY2018 revenue has already exceeded total revenue for FY2017 For personal use only Acquired in 2013 from Japanese owners with revenues increasing Advangen revenue 4X since acquisition, CAGR of 57% over period FY14

  15. Slide 15: Growth Drivers

    Slide 15: Growth Drivers

    GROWTH DRIVERS Growth is expected to come from four broad categories: New products For personal use only • Extension of the product range (new products, refer to right) Revive & Lift Spray • Distribution channel expansion in existing markets Non-comedogenic dry • Geographical expansion within USA, C

  16. Slide 16: Australia

    Slide 16: Australia

    AUSTRALIA For personal use only Existing Channels • E-commerce: Dedicated global website launched in April 2018, including the AU portal • Pharmacy: évolis® products are stocked in over 1,800 pharmacies (up from 1,000 in FY2017) accounting for around 35% of the market • Servicing selected premium sa

  17. Slide 17: Japan

    Slide 17: Japan

    JAPAN Existing Channels HIGHLIGHTS For personal use only • QVC TV shopping: Continue to market through television shopping channel QVC Japan, providing exposure to 26 million households. QVC Japan accounts for 65% of Japanese revenue. • Barbershops: Service barbershop network via Japan’s largest who

  18. Slide 18: USA

    Slide 18: USA

    USA HIGHLIGHTS For personal use only Existing Channels • E-commerce: Currently limited activity (to increase after the launch of fully operational website) • Premium retail: Partnerships entered into with Neiman Marcus started in September 2017, Soft Surroundings in April 2018 and Bloomingdales will

  19. Slide 19: China

    Slide 19: China

    CHINA Existing and near term channels For personal use only • Distribution agreement: Exclusive five-year agreement signed in May 2018 with Fukangren Bio- Pharm Tech. Co. Ltd for the distribution of évolis® lotions and shampoos to over 500 pharmacies, associated hospitals and clinics in China. The a

  20. Slide 20: Business Performance & Outlook

    Slide 20: Business Performance & Outlook

    For personal use only BUSINESS PERFORMANCE & OUTLOOK 20

  21. Slide 21: Financial Performance

    Slide 21: Financial Performance

    FINANCIAL PERFORMANCE For personal use only 6 Months Ended 31 Dec H1 2018 H1 2017 (A$’Ms) (A$’Ms) % chg Q3 2018 Quarterly Update Consumer health revenue 3.1 2.0 50.3% • Record receipts from customers of Midkine & license revenue 0.1 0.1 (1.3)% $2.2 million, an increase of 81% in Other income 1.0 0.8

  22. Slide 22: Anticipated Newsflow

    Slide 22: Anticipated Newsflow

    ANTICIPATED NEWSFLOW Record $2 million China distribution For personal use only Tokyo concept store consumer health agreement launch sales $ Fillerina Targeted Cellmid news flow: Placement to Dennis agreement .60 Eck • Launch of new global website • New product launches .40 • Additional retail partn

  23. Slide 23: Lyramid & Kinera: Midkine in Therapy

    Slide 23: Lyramid & Kinera: Midkine in Therapy

    For personal use only Lyramid & Kinera Midkine in therapy 23

  24. Slide 24: Midkine – A Novel and Compelling Target

    Slide 24: Midkine – A Novel and Compelling Target

    MIDKINE – A NOVEL AND COMPELLING TARET Discovered in 1988, midkine is the subject of over 815 publications (300+ in oncology) For personal use only • CDY has the largest portfolio of midkine IP assets globally with several Midkine Overexpression relative to healthy tissue Tissue Blood Urine potentia

  25. Slide 25: Lyramid and Kinera

    Slide 25: Lyramid and Kinera

    LYRAMID KINERA • Stage: pre-clinical • Stage: pre-clinical • Drug class: Antibodies CAB101 and CAB102 (cancer, fibrosis, • Drug class: Protein, MK For personal use only chronic kidney disease, myocarditis) and companion diagnostic • Applications: heart failure, chronic heart conditions and ischemia

  26. Slide 26: Objectives for Lyramid & Kinera in 2018

    Slide 26: Objectives for Lyramid & Kinera in 2018

    OBJECTIVES FOR LYRAMID & KINERA IN 2018 For personal use only Complete pre-clinical studies to enter clinical development • Clinical indications will be assessed on the strength of pre-clinical evidence during 2018 • Focused on capital preservation - partnerships are the preferred strategic approach

  27. Slide 27: Appendices

    Slide 27: Appendices

    For personal use only APPENDICES 27

  28. Slide 28: Who are QVC?

    Slide 28: Who are QVC?

    WHO ARE QVC? For personal use only QVC is a multiplatform shopping experience engaging millions QVC Global Scale of shoppers with hundreds of brands globally through online, Country TV Homes Channels broadcasting, mobile and social channels. (Millions) United States 104 3 The QVC business model allo

  29. Slide 29: FGF5 and evolis Publications in Peer Reviewed Journals

    Slide 29: FGF5 and evolis Publications in Peer Reviewed Journals

    FGF5 AND EVOLIS PUBLICATIONS IN PEER REVIEWED JOURNALS – SCIENTIFIC AND CLINICAL VALIDATION For personal use only • Maeda T., Yamamoto T., Isikawa Y. Sanguisorba Officinalis Root Extract has FGF5 Inhibitory activity and reduces hair loss by causing prolongation of the anagen period. Skin research an

  30. Slide 30: Disclaimer

    Slide 30: Disclaimer

    For personal use only DISCLAIMER Forward looking statements This presentation contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially di

Source: Internet Archive copy of anagenics.com

More decks from Anagenics Limited

All 38 Anagenics decks